Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced Upper Tract Urothelial Carcinoma: a Prospective Observational Cohort Study
Latest Information Update: 01 Oct 2024
Price :
$35 *
At a glance
- Drugs Tislelizumab (Primary)
- Indications Pelvic cancer; Urethral cancer
- Focus Therapeutic Use
- Acronyms LUXUS2-1
- 01 Oct 2024 New trial record